Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has received a consensus recommendation of "Hold" from the twelve analysts that are presently covering the stock, Marketbeat.com reports. Twelve research analysts have rated the stock with a hold rating. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $13.31.
A number of analysts recently commented on the company. Royal Bank of Canada decreased their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating for the company in a research report on Tuesday, March 4th. Leerink Partnrs lowered Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. downgraded shares of Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, February 10th. Stifel Nicolaus lowered shares of Pliant Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Leerink Partners lowered shares of Pliant Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $33.00 to $2.00 in a research report on Monday, March 3rd.
Read Our Latest Research Report on Pliant Therapeutics
Insider Buying and Selling
In other Pliant Therapeutics news, insider Hans Hull sold 15,936 shares of the firm's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $178,483.20. Following the sale, the insider now owns 211,558 shares of the company's stock, valued at $2,369,449.60. This trade represents a 7.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Mike Ouimette sold 10,230 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total value of $112,427.70. Following the transaction, the general counsel now owns 70,544 shares of the company's stock, valued at approximately $775,278.56. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 91,855 shares of company stock worth $1,026,628. Insiders own 6.40% of the company's stock.
Institutional Investors Weigh In On Pliant Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Atria Investments Inc purchased a new stake in shares of Pliant Therapeutics during the third quarter valued at approximately $112,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Pliant Therapeutics during the 3rd quarter valued at $388,000. Intech Investment Management LLC bought a new stake in shares of Pliant Therapeutics in the 3rd quarter worth $145,000. Charles Schwab Investment Management Inc. raised its stake in shares of Pliant Therapeutics by 4.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 456,663 shares of the company's stock worth $5,119,000 after purchasing an additional 19,281 shares during the last quarter. Finally, Algert Global LLC lifted its holdings in shares of Pliant Therapeutics by 52.6% during the third quarter. Algert Global LLC now owns 106,562 shares of the company's stock valued at $1,195,000 after purchasing an additional 36,720 shares in the last quarter. 97.30% of the stock is owned by institutional investors.
Pliant Therapeutics Stock Up 9.4 %
NASDAQ PLRX traded up $0.14 on Friday, reaching $1.57. The company had a trading volume of 2,217,447 shares, compared to its average volume of 861,483. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The company's fifty day moving average is $7.88 and its 200 day moving average is $11.39. Pliant Therapeutics has a 52-week low of $1.26 and a 52-week high of $16.52. The stock has a market capitalization of $95.83 million, a P/E ratio of -0.47 and a beta of 1.18.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.17. Sell-side analysts anticipate that Pliant Therapeutics will post -3.64 earnings per share for the current fiscal year.
About Pliant Therapeutics
(
Get Free ReportPliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Read More
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
